Johnson & Johnson

In 2016 Greenpeace published a report on the progress towards zero deforestation in the palm oil supply chains of several multinational companies. Companies were assessed on three criteria: responsible sourcing, transparency and industry reform. This company was rated as 'failed promises'.
Source: Greenpeace (2016)

This company sources palm oil from 19 of the 25 dirty palm oil producers identified in the 2018 Greenpeace report "The Final Countdown". In addition to deforestation, the 25 individual cases in the report include evidence of exploitation and social conflicts, illegal deforestation, development without permits, plantation development in areas zoned for protection and forest fires linked to land clearance.
Source: Greenpeace (2018)

The Talking Trash 2020 report by Changing Markets investigates the corporate playbook of false solutions to the plastic crisis. It found that the industry is actively delaying and derailing ambitious action on plastic pollution in its fight to maintain business as usual for as long as possible. For example, this company is signed up to 3 nice-sounding voluntary initiatives to address plastic waste, while also participating in two industry associations which lobby against legislation that could restrict plastic, or make corporations responsible for managing the waste they create, financially or otherwise.
Source: Changing Markets (2020)

In October 2016 this company lost a third straight trial over claims its talcum powder can cause ovarian cancer with a jury awarding a California woman more than $70 million, following damages verdicts of $72 million and $55 million earlier in 2016. J&J is facing another 1,700 similar lawsuits over its talcum products
Source: Bloomberg (2016)

DePuy Orthopaedics, a division of this company, has 3 hip replacement devices that have had a high failure rate, causing permanent injury to patients and requirements for revision and reconstruction surgery in a number of patients. The company has more than 7000 lawsuits pending in Federal US courts and 2000 lawsuits pending in California state courts. The company has set aside US$2b for settlements. The first lawsuits filed in state courts were settled in August 2012, awarding approximately US$200,000 to each victim.
Source: Drug Dangers (2014)

As a result of the effects and inappropriate marketing of its antipsychotic drug Risperdal, this company was fined US$1.2b in 2012 in the Arkansas Federal Court due to claims the company downplayed risks and that over 240,000 cases of Medicaid fraud and 4,500 deceptive practices had been caused by the manufacturers marketing activity. Also in 2012 the company settled lawsuits with 36 US states and the District of Columbia regarding improper marketing techniques, specifically for the treatment of children. The cases were settled by the payment of US$181m. Other state cases were also settled including US$327m in South Carolina, US$258m in Louisiana and US$158m in Texas. The company continues to face hundreds of lawsuits regarding Risperdal.
Source: Drug Dangers (2012)

In July 2018 this company was ordered to pay a record US$4.69 billion to 22 women in the US who alleged the company's talc-based products contained asbestos and caused them to develop ovarian cancer. Johnson & Johnson is currently battling around 9000 talc cases.
Source: news article (2018)

In 2013, in one of the largest health care fraud settlements in US history, Johnson & Johnson agreed to pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by the Food and Drug Administration (FDA) and payment of kickbacks to physicians and to the nation's largest long-term care pharmacy provider.
Source: US Dept of Justice (2013)

This company appears on PETA's (People for the Ethical Treatment of Animals, USA) 'Companies That Do Test On Animals' list, signifying that they manufacture products that are tested on animals at some stage of development.
Source: PETA (2020)

This company received a score of 10.3/100 (retrieved 10-Oct-2020) in the Corporate Information Transparency Index (CITI), a system for evaluating supply chain practices in China, particularly in regards to environmental management and water pollution. Scores are calculated using government compliance data, online monitoring data, and third-party environmental audits, as well as trends in the environmental performance of factories in the company's supply chains.
Source: IPE (2020)

In 2010, Johnson & Johnson subsidiary Ortho-McNeil pleaded guilty to illegally promoting Topamax and agreed to pay a $6.14 million fine. That year, its affiliate, Ortho-McNeil-Janssen Pharmaceuticals, also agreed to pay $75.37 million to resolve similar allegations under the federal False Claims Act. Topamax has been linked to birth defects. In 2013 juries awarded $4 million to one family and $11 million to another over birth defects. More court cases and pending.
Source: Drug Watch (2013)

In 2019 this company was ordered by a US judge to pay US$572 million for its part in the opioid addiction crisis in Oklahoma, USA. Judge Thad Balkman said that J&J has became a "public nuisance" in promoting the addictive prescription painkillers to consumers in the state.
Source: news article (2019)

In 2019 several pharmaceutical companies finally settled a 2005 lawsuit which claimed the companies fudged wholesale drug prices to increase Medicaid reimbursements. In all, the state of Illinois received a combined $648 million over the course of that litigation. This company paid US$49.5 million in the 2019 settlement.
Source: news article (2019)

A 2018 report by Oxfam shows that four pharmaceutical corporations, including this one, systematically hide their profits in overseas tax havens. This activity could deprive developing countries of more than $100 million every year. These corporations deploy massive influencing operations to rig the rules in their favor and give their damaging behavior a veneer of legitimacy. Tax dodging, high prices, and influence peddling by drug companies exacerbate the yawning gap between rich and poor, between men and women, and between advanced economies and developing ones.
Source: Oxfam (2018)

In 2019 the median pay for a worker at this company was US$76,000. The CEO was paid 334 times this amount. Exorbitant CEO pay is a major contributor to rising inequality. CEOs are getting more because of their power to set pay, not because they are increasing productivity or possess specific, high-demand skills. The economy would suffer no harm if CEOs were paid less (or taxed more). In contrast, the CEO-to-typical-worker compensation ratio was 20-to-1 in 1965 and 58-to-1 in 1989.
Source: AFL-CIO (2020)